Product Reports Resources Pricing Login Book a demo

Kite Pharma

Biotech & Life Sciences · Santa Monica, United States · Founded 2009 · IPO 2014

Immune-based therapies to treat cancer indications

Valuation $12B
Revenue $20M
Power Law Decacorn$10B+ valuation tier
Featured in
News Gilead to buy Arcellx for $7.8B to secure cancer therapy anito-cel Feb 23, 2026

Investors

9 investors on Kite Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Two River
Riverbank Capital Securities
Lee Linden
Alta Partners
Series B+ 5 investors entered at this stage
National Cancer Institute (NCI)
Arie Belldegrun
Weizmann Institute of Science
University of California
Los Angeles

Global footprint

Where Kite Pharma has talent and traffic

Workforce by country
33 countries with
team presence
🇺🇸 United States66.6%
🇳🇱 Netherlands24.4%
🇬🇧 United Kingdom2.4%
🇪🇸 Spain0.9%
🇮🇪 Ireland0.9%
Top 5 of 33 shown
Web traffic by country
20K monthly visits
across markets
🇺🇸 United States60.5%
🇳🇱 Netherlands12.5%
🇬🇧 United Kingdom9.5%
🇮🇳 India6.5%
🇵🇭 Philippines4%
Top 5 markets shown

Talent graph

The shape of Kite Pharma's talent

Dealroom maps Kite Pharma's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 standout operatorsDealroom-flagged across the org
16 AI specialistsincl. 2 core researchers
4,029 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Kite Pharma's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$199M patent portfolio · 176 active families

Estimated portfolio value
$199M
1.7% of market cap · comparable to top peer Autolus ($150M)
176 active patent families
Where Kite Pharma innovates Antigen bindingAntigen receptorsCancer researchCell biologyCell therapy

Where Kite Pharma concentrates vs peers

Each axis is a top-10 topic across Kite Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Kite Pharma's 14 investments and acquisitions.

Every disclosed deal where Kite Pharma appeared as a backer or acquirer, 2016–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

14 deals across Kite Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Kite Pharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        14 of 14 deals

        Market sentiment

        What the market is saying about Kite Pharma

        An AI-synthesized read of the highest-engagement posts about Kite Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Kite Pharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles